BACKGROUND: This study investigates whether there has been any survival improvement for @entity157 @entity1 with resectable and unresectable lung metastases over time. METHODS: The data of 280 @entity157 @entity1 who developed metachronous lung metastases after hepatectomy with curative intent were analysed. Overall survival was compared in @entity1 with resectable and unresectable lung metastases and in different periods ( @entity7971 I: 1989-1995, @entity7971 II: 1996-2010). RESULTS: The median overall survival of @entity1 with unresectable and resectable diseases was 7.46 and 40.36 months, respectively (P < 0.0001). In @entity7971 I, the median overall survival of @entity1 with unresectable and resectable diseases was 5.59 and 43.15 months, respectively (P < 0.0001). The corresponding figures in @entity7971 II were 8.38 and 32.90 months (P < 0.0001). The overall survival of @entity1 with resectable disease did not differ significantly in the two eras but there was a significant improvement in survival of @entity1 with unresectable disease in @entity7971 II. Their 1-year, 3-year and 5-year survival rates in @entity7971 I versus @entity7971 II were 11.1% versus 38.4%, 5.6% versus 9.1% and 2.8% versus 3.5%, respectively (P = 0.041). The corresponding figures for their counterparts in the resectable group were 90% versus 85.8%, 80% versus 45.9% and 40% versus 29.5%, respectively (P = 0.443). CONCLUSIONS: @entity1 with resectable lung metastases had better overall survival than those with unresectable lung metastases. Notably, @entity1 with unresectable lung metastases had significant improvement in survival over the years.

Retrospective study of metachronous lung metastases from primary XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma'] @entity7971 :: ('26284', 'Gene') :: ['Era']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
